These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

914 related articles for article (PubMed ID: 12154405)

  • 21. Epigenetic abnormalities in cutaneous squamous cell carcinomas: frequent inactivation of the RB1/p16 and p53 pathways.
    Murao K; Kubo Y; Ohtani N; Hara E; Arase S
    Br J Dermatol; 2006 Nov; 155(5):999-1005. PubMed ID: 17034532
    [TBL] [Abstract][Full Text] [Related]  

  • 22. DNMT1 is required to maintain CpG methylation and aberrant gene silencing in human cancer cells.
    Robert MF; Morin S; Beaulieu N; Gauthier F; Chute IC; Barsalou A; MacLeod AR
    Nat Genet; 2003 Jan; 33(1):61-5. PubMed ID: 12496760
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of DNA from human stools to detect aberrant CpG island methylation of genes implicated in colorectal cancer.
    Belshaw NJ; Elliott GO; Williams EA; Bradburn DM; Mills SJ; Mathers JC; Johnson IT
    Cancer Epidemiol Biomarkers Prev; 2004 Sep; 13(9):1495-501. PubMed ID: 15342451
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Distinct promoter hypermethylation of p16INK4a, CDH1, and RAR-beta in intestinal, diffuse-adherent, and diffuse-scattered type gastric carcinomas.
    Oue N; Motoshita J; Yokozaki H; Hayashi K; Tahara E; Taniyama K; Matsusaki K; Yasui W
    J Pathol; 2002 Sep; 198(1):55-9. PubMed ID: 12210063
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical implications of aberrant DNA methylation patterns in acute myelogenous leukemia.
    Galm O; Wilop S; Lüders C; Jost E; Gehbauer G; Herman JG; Osieka R
    Ann Hematol; 2005 Dec; 84 Suppl 1():39-46. PubMed ID: 16231140
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hypermethylation trigger of the glutathione-S-transferase gene (GSTP1) in prostate cancer cells.
    Song JZ; Stirzaker C; Harrison J; Melki JR; Clark SJ
    Oncogene; 2002 Feb; 21(7):1048-61. PubMed ID: 11850822
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epigenetic inactivation of RAS association domain family protein 1 (RASSF1A) in malignant cutaneous melanoma.
    Spugnardi M; Tommasi S; Dammann R; Pfeifer GP; Hoon DS
    Cancer Res; 2003 Apr; 63(7):1639-43. PubMed ID: 12670917
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Frequent epigenetic inactivation of the RASSF1A tumour suppressor gene in testicular tumours and distinct methylation profiles of seminoma and nonseminoma testicular germ cell tumours.
    Honorio S; Agathanggelou A; Wernert N; Rothe M; Maher ER; Latif F
    Oncogene; 2003 Jan; 22(3):461-6. PubMed ID: 12545168
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epigenetic inactivation of the RASSF1A tumour suppressor gene in ependymoma.
    Hamilton DW; Lusher ME; Lindsey JC; Ellison DW; Clifford SC
    Cancer Lett; 2005 Sep; 227(1):75-81. PubMed ID: 16051033
    [TBL] [Abstract][Full Text] [Related]  

  • 30. DNA hypermethylation: when tumour suppressor genes go silent.
    Garinis GA; Patrinos GP; Spanakis NE; Menounos PG
    Hum Genet; 2002 Aug; 111(2):115-27. PubMed ID: 12189484
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The roles of DNA methylation in human neoplasms].
    Yuan YF; Li JQ; Yang ZL; Wang JP
    Ai Zheng; 2002 Nov; 21(11):1267-77. PubMed ID: 12526230
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aberrant methylation of p14(ARF), p15(INK4b) and p16(INK4a) genes and location of the primary site in pulmonary squamous cell carcinoma.
    Furonaka O; Takeshima Y; Awaya H; Ishida H; Kohno N; Inai K
    Pathol Int; 2004 Aug; 54(8):549-55. PubMed ID: 15260845
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hypermethylation of gene promoters in hematological neoplasia.
    Chim CS; Liang R; Kwong YL
    Hematol Oncol; 2002 Dec; 20(4):167-76. PubMed ID: 12469326
    [TBL] [Abstract][Full Text] [Related]  

  • 34. DNA methylation and gene silencing in cancer: which is the guilty party?
    Clark SJ; Melki J
    Oncogene; 2002 Aug; 21(35):5380-7. PubMed ID: 12154400
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epigenetic silencing mediated by CpG island methylation: potential as a therapeutic target and as a biomarker.
    Teodoridis JM; Strathdee G; Brown R
    Drug Resist Updat; 2004; 7(4-5):267-78. PubMed ID: 15533764
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biallelic epigenetic inactivation of the RASSF1A tumor suppressor gene in medulloblastoma development.
    Lusher ME; Lindsey JC; Latif F; Pearson AD; Ellison DW; Clifford SC
    Cancer Res; 2002 Oct; 62(20):5906-11. PubMed ID: 12384556
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genome-wide profiling of CpG methylation identifies novel targets of aberrant hypermethylation in myeloid leukemia.
    Gebhard C; Schwarzfischer L; Pham TH; Schilling E; Klug M; Andreesen R; Rehli M
    Cancer Res; 2006 Jun; 66(12):6118-28. PubMed ID: 16778185
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inactivation of the lamin A/C gene by CpG island promoter hypermethylation in hematologic malignancies, and its association with poor survival in nodal diffuse large B-cell lymphoma.
    Agrelo R; Setien F; Espada J; Artiga MJ; Rodriguez M; Pérez-Rosado A; Sanchez-Aguilera A; Fraga MF; Piris MA; Esteller M
    J Clin Oncol; 2005 Jun; 23(17):3940-7. PubMed ID: 15867203
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CpG island methylator phenotypes in aging and cancer.
    Toyota M; Issa JP
    Semin Cancer Biol; 1999 Oct; 9(5):349-57. PubMed ID: 10547343
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A comprehensive catalog of CpG islands methylated in human lung adenocarcinomas for the identification of tumor suppressor genes.
    Shiraishi M; Sekiguchi A; Terry MJ; Oates AJ; Miyamoto Y; Chuu YH; Munakata M; Sekiya T
    Oncogene; 2002 May; 21(23):3804-13. PubMed ID: 12032849
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 46.